Daily Stock Analysis, APHB, AmpliPhi Biosciences Corp, priceseries

AmpliPhi Biosciences Corp. Daily Stock Analysis
Stock Information
Open
0.26
Close
0.26
High
0.26
Low
0.25
Previous Close
0.25
Daily Price Gain
0.01
YTD High
0.31
YTD High Date
Jan 4, 2019
YTD Low
0.21
YTD Low Date
Jan 2, 2019
YTD Price Change
0.02
YTD Gain
9.27%
52 Week High
1.69
52 Week High Date
Mar 9, 2018
52 Week Low
0.15
52 Week Low Date
Dec 18, 2018
52 Week Price Change
-1.02
52 Week Gain
-79.92%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 12. 2017
5.40
Jan 13. 2017
6.10
1 Trading Days
12.97%
Link
LONG
Apr 24. 2017
3.54
Apr 25. 2017
4.27
1 Trading Days
20.62%
Link
LONG
Sep 5. 2017
0.86
Sep 25. 2017
1.01
14 Trading Days
17.04%
Link
LONG
Oct 11. 2017
1.09
Oct 19. 2017
1.20
6 Trading Days
9.86%
Link
LONG
Feb 20. 2018
1.33
Feb 21. 2018
1.40
1 Trading Days
5.26%
Link
Company Information
Stock Symbol
APHB
Exchange
NYSE MKT
Company URL
http://www.ampliphibio.com
Company Phone
804-827-2524
CEO
M. Scott Salka
Headquarters
California
Business Address
3579 VALLEY CENTRE DRIVE, SAN DIEGO, CA 92130
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0000921114
About

AmpliPhi Biosciences Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel phage therapeutics. It operates in segments of the biotechnology and biopharmaceutical markets. The company was founded in March 1989 and is headquartered in San Diego, CA.

Description

AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the discovery, development, and commercialization of various bacteriophage therapeutics. Its lead product candidate comprises AB-SA01 that is in Phase I clinical trial for the treatment of Staphylococcus aureus (S. aureus) infections, including methicillin-resistant S. aureus. The company's products under development include AB-PA01 for the treatment of Pseudomonas aeruginosa lung infections in cystic fibrosis patients; and AB-CD01 for the treatment of Clostridium difficile infections. It has a collaboration agreement with Intrexon Corporation to utilize synthetic biology platform for the identification, development, and production of bacteriophage-containing human therapeutics. The company was formerly known as Targeted Genetics Corporation and changed its name to AmpliPhi Biosciences Corporation in February 2011. AmpliPhi Biosciences Corporation was founded in 1989 and is based in San Diego, California.